Mark Emmanuel Cooper

Title: Mark Emmanuel Cooper: Innovator in Diabetic Nephropathy Treatment

Introduction

Mark Emmanuel Cooper is a notable inventor based in Prahran, Australia. He has made significant contributions to the field of medical treatment, particularly in addressing diabetic nephropathy. His innovative approach has led to the development of a unique pharmaceutical composition aimed at improving the lives of those affected by this condition.

Latest Patents

Mark Emmanuel Cooper holds a patent for the "Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy." This invention focuses on the application of PDGF receptor tyrosine kinase inhibitors, specifically N-phenyl-2-pyrimidine-amine derivatives, in the manufacture of pharmaceutical compositions. The patent outlines methods for treating warm-blooded animals, including humans, suffering from diabetic nephropathy. It also details the use of these inhibitors in the treatment of related conditions such as glomerulonephritis, chronic pyelonephritis, and IgA nephropathy.

Career Highlights

Throughout his career, Mark has demonstrated a commitment to advancing medical science through his innovative research and development efforts. His work has not only contributed to the understanding of diabetic nephropathy but has also paved the way for new treatment options that can significantly enhance patient care.

Collaborations

Mark has collaborated with esteemed colleagues, including Prudence Ann Hill and Richard Ernest Gilbert. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their collective work.

Conclusion

Mark Emmanuel Cooper's contributions to the field of diabetic nephropathy treatment exemplify the importance of innovation in medicine. His patent and collaborative efforts highlight the potential for new therapies that can improve patient outcomes.